BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 25556051)

  • 1. Molecular characterization and antifungal susceptibility of Cryptococcus neoformans strains collected from a single institution in Lima, Peru.
    Bejar V; Tello M; García R; Guevara JM; Gonzales S; Vergaray G; Valencia E; Abanto E; Ortega-Loayza AG; Hagen F; Gutierrez EL
    Rev Iberoam Micol; 2015; 32(2):88-92. PubMed ID: 25556051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular epidemiology and antifungal susceptibility of Serbian Cryptococcus neoformans isolates.
    Arsic Arsenijevic V; Pekmezovic MG; Meis JF; Hagen F
    Mycoses; 2014 Jun; 57(6):380-7. PubMed ID: 24438323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
    Hagen F; Hare Jensen R; Meis JF; Arendrup MC
    Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbiological characteristics of clinical isolates of Cryptococcus neoformans in Taiwan: serotypes, mating types, molecular types, virulence factors, and antifungal susceptibility.
    Liaw SJ; Wu HC; Hsueh PR
    Clin Microbiol Infect; 2010 Jun; 16(6):696-703. PubMed ID: 19694765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro antifungal susceptibilities and molecular typing of sequentially isolated clinical Cryptococcus neoformans strains from Croatia.
    Mlinarić-Missoni E; Hagen F; Chew WHM; Važić-Babić V; Boekhout T; Begovac J
    J Med Microbiol; 2011 Oct; 60(Pt 10):1487-1495. PubMed ID: 21617022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization and antifungal susceptibility testing of Cryptococcus neoformans sensu stricto from southern Brazil.
    Herkert PF; Meis JF; Lucca de Oliveira Salvador G; Rodrigues Gomes R; Aparecida Vicente V; Dominguez Muro M; Lameira Pinheiro R; Lopes Colombo A; Vargas Schwarzbold A; Sakuma de Oliveira C; Simão Ferreira M; Queiroz-Telles F; Hagen F
    J Med Microbiol; 2018 Apr; 67(4):560-569. PubMed ID: 29461182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.
    Chowdhary A; Randhawa HS; Sundar G; Kathuria S; Prakash A; Khan Z; Sun S; Xu J
    J Med Microbiol; 2011 Jul; 60(Pt 7):961-967. PubMed ID: 21393452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifungal susceptibility, serotyping, and genotyping of clinical Cryptococcus neoformans isolates collected during 18 years in a single institution in Madrid, Spain.
    Guinea J; Hagen F; Peláez T; Boekhout T; Tahoune H; Torres-Narbona M; Bouza E
    Med Mycol; 2010 Nov; 48(7):942-8. PubMed ID: 20297948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular typing and antifungal susceptibility of clinical and environmental Cryptococcus neoformans species complex isolates in Goiania, Brazil.
    Souza LK; Souza Junior AH; Costa CR; Faganello J; Vainstein MH; Chagas AL; Souza AC; Silva MR
    Mycoses; 2010 Jan; 53(1):62-7. PubMed ID: 19500261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotype and mating type analysis of Cryptococcus neoformans and Cryptococcus gattii isolates from China that mainly originated from non-HIV-infected patients.
    Feng X; Yao Z; Ren D; Liao W; Wu J
    FEMS Yeast Res; 2008 Sep; 8(6):930-8. PubMed ID: 18671745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotyping and antifungal susceptibility testing of Cryptococcus neoformans isolates from Cameroonian HIV-positive adult patients.
    Bertout S; Drakulovski P; Kouanfack C; Krasteva D; Ngouana T; Dunyach-Rémy C; Dongtsa J; Aghokeng A; Delaporte E; Koulla-Shiro S; Reynes J; Mallié M
    Clin Microbiol Infect; 2013 Aug; 19(8):763-9. PubMed ID: 23033854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular typing and in vitro antifungal susceptibility of Cryptococcus spp from patients in Midwest Brazil.
    Favalessa OC; de Paula DA; Dutra V; Nakazato L; Tadano T; Lazera Mdos S; Wanke B; Trilles L; Walderez Szeszs M; Silva D; Hahn RC
    J Infect Dev Ctries; 2014 Aug; 8(8):1037-43. PubMed ID: 25116671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular identification, antifungal resistance and virulence of Cryptococcus neoformans and Cryptococcus deneoformans isolated in Seville, Spain.
    Gago S; Serrano C; Alastruey-Izquierdo A; Cuesta I; Martín-Mazuelos E; Aller AI; Gómez-López A; Mellado E
    Mycoses; 2017 Jan; 60(1):40-50. PubMed ID: 27633849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predominance of Cryptococcus neoformans var. grubii multilocus sequence type 5 and emergence of isolates with non-wild-type minimum inhibitory concentrations to fluconazole: a multi-centre study in China.
    Fan X; Xiao M; Chen S; Kong F; Dou HT; Wang H; Xiao YL; Kang M; Sun ZY; Hu ZD; Wan Z; Chen SL; Liao K; Chu YZ; Hu TS; Zou GL; Hou X; Zhang L; Zhao YP; Xu YC; Liu ZY
    Clin Microbiol Infect; 2016 Oct; 22(10):887.e1-887.e9. PubMed ID: 27432767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Characterization and Antifungal Susceptibility Testing of Sequentially Obtained Clinical Cryptococcus deneoformans and Cryptococcus neoformans Isolates from Ljubljana, Slovenia.
    Tomazin R; Matos T; Meis JF; Hagen F
    Mycopathologia; 2018 Apr; 183(2):371-380. PubMed ID: 29064061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular typing of clinical isolates of Cryptococcus neoformans/Cryptococcus gattii species complex from Northeast Mexico.
    González GM; Casillas-Vega N; Garza-González E; Hernández-Bello R; Rivera G; Rodríguez JA; Bocanegra-Garcia V
    Folia Microbiol (Praha); 2016 Jan; 61(1):51-6. PubMed ID: 26109075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular typing and in vitro resistance of Cryptococcus neoformans clinical isolates obtained in Germany between 2011 and 2017.
    Selb R; Fuchs V; Graf B; Hamprecht A; Hogardt M; Sedlacek L; Schwarz R; Idelevich EA; Becker SL; Held J; Küpper-Tetzel CP; McCormick-Smith I; Heckmann D; Gerkrath J; Han CO; Wilmes D; Rickerts V
    Int J Med Microbiol; 2019 Sep; 309(6):151336. PubMed ID: 31444102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular typing of clinical Cryptococcus neoformans isolates collected in Germany from 2004 to 2010.
    Sanchini A; Smith IM; Sedlacek L; Schwarz R; Tintelnot K; Rickerts V
    Med Microbiol Immunol; 2014 Oct; 203(5):333-40. PubMed ID: 24838744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel hybrids between Cryptococcus neoformans var. grubii VNI and Cryptococcus gattii VGII.
    Aminnejad M; Diaz M; Arabatzis M; Castañeda E; Lazera M; Velegraki A; Marriott D; Sorrell TC; Meyer W
    Mycopathologia; 2012 Jun; 173(5-6):337-46. PubMed ID: 22081254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative typing analyses of clinical and environmental strains of the Cryptococcus neoformans/Cryptococcus gattii species complex from Ivory Coast.
    Kassi FK; Bellet V; Drakulovski P; Krasteva D; Roger F; Valérie BA; Aboubakar T; Doumbia A; Kouakou GA; Delaporte E; Reynes J; Yavo W; Menan HIE; Bertout S
    J Med Microbiol; 2018 Jan; 67(1):87-96. PubMed ID: 29214970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.